GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tauns Laboratories Inc (TSE:197A) » Definitions » Total Stockholders Equity

Tauns Laboratories (TSE:197A) Total Stockholders Equity : 円16,291 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Tauns Laboratories Total Stockholders Equity?

Tauns Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2024 was 円16,291 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Tauns Laboratories's Book Value per Share for the quarter that ended in Dec. 2024 was 円160.05. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Tauns Laboratories's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.82.

Tauns Laboratories Total Stockholders Equity Historical Data

The historical data trend for Tauns Laboratories's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tauns Laboratories Total Stockholders Equity Chart

Tauns Laboratories Annual Data
Trend Jun22 Jun23 Jun24
Total Stockholders Equity
7,356.31 8,489.87 13,666.76

Tauns Laboratories Quarterly Data
Jun22 Jun23 Mar24 Jun24 Dec24
Total Stockholders Equity 7,356.31 8,489.87 13,794.51 13,666.76 16,291.14

Tauns Laboratories  (TSE:197A) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Tauns Laboratories's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(16291.14-0)/101.785
=160.05

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Tauns Laboratories's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5232 + 8083) / 16291.14
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tauns Laboratories Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Tauns Laboratories's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tauns Laboratories Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tauns Laboratories Inc (TSE:197A) » Definitions » Total Stockholders Equity
Comparable Companies
TSE:5889 TSE:262A TSE:7749 TSE:7979 TSE:7780 TSE:3593 TSE:3154 TSE:7743 TSE:7775 TSE:7702 ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD TSE:4543 OCSE:COLO B XPAR:DIM XSWX:STMN
Traded in Other Exchanges
N/A
Address
761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325
Website
https://www.tauns.co.jp/en
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.

Tauns Laboratories Headlines

No Headlines